AHA Scientific Statement 852 Abstract—The year 2014 marked the 20th anniversary of the coining of the term proteomics. The purpose of this scientific statement is to summarize advances over this period that have catalyzed our capacity to address the experimental, translational, and clinical implications of proteomics as applied to cardiovascular health and disease and to evaluate the current status of the field. Key successes that have energized the field are delineated; opportunities for proteomics to drive basic science research, facilitate clinical translation, and establish diagnostic and therapeutic healthcare algorithms are discussed; and challenges that remain to be solved before proteomic technologies can be readily translated from scientific discoveries to meaningful advances in cardiovascular care are addressed. Proteomics is the result of disruptive technologies, namely, mass spectrometry and database searching, which drove protein analysis from 1 protein at a time to protein mixture analyses that enable large-scale analysis of proteins and facilitate paradigm shifts in biological concepts that address important clinical questions. Over the past 20 years, the field of proteomics has matured, yet it is still developing rapidly. The scope of this statement will extend beyond the reaches of a typical review article and offer guidance on the use of next-generation proteomics for future scientific discovery in the basic research laboratory and clinical settings. (Circulation. 2015;132:852-872. DOI: 10.1161/CIR.0000000000000226.) Key Words: AHA Scientific Statements ◼ biomarkers ◼ mass spectrometry ◼ proteome ◼ systems biology ◼ translational research © 2015 American Heart Association, Inc. Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIR.0000000000000226 The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association. The views expressed are those of the authors and do not necessarily reflect the positions of the National Heart, Lung, and Blood Institute or the US government. The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest. This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on April 22, 2015, and the American Heart Association Executive Committee on May 22, 2015. A copy of the document is available at http://my.americanheart.org/statements by selecting either the “By Topic” link or the “By Publication Date” link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com. The American Heart Association requests that this document be cited as follows: Lindsey ML, Mayr M, Gomes AV, Delles C, Arrell DK, Murphy AM, Lange RA, Costello CE, Jin Y-F, Laskowitz DT, Sam F, Terzic A, Van Eyk J, Srinivas PR; on behalf of the American Heart Association Council on Functional Genomics and Translational Biology, Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Hypertension, and Stroke Council. Transformative impact of proteomics on cardiovascular health and disease: a scientific statement from the American Heart Association. Circulation. 2015;132:852–872. Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://my.americanheart.org/statements and select the “Policies and Development” link. Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright- Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page. Transformative Impact of Proteomics on Cardiovascular Health and Disease A Scientific Statement From the American Heart Association Merry L. Lindsey, PhD, FAHA, Chair; Manuel Mayr, MD, PhD, FAHA, Co-Chair; Aldrin V. Gomes, PhD; Christian Delles, MD, FAHA; D. Kent Arrell, PhD; Anne M. Murphy, MD, FAHA; Richard A. Lange, MD, FAHA; Catherine E. Costello, PhD; Yu-Fang Jin, PhD; Daniel T. Laskowitz, MD, FAHA; Flora Sam, MD, FAHA; Andre Terzic, MD, PhD, FAHA; Jennifer Van Eyk, PhD, FAHA; Pothur R. Srinivas, PhD; on behalf of the American Heart Association Council on Functional Genomics and Translational Biology, Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Hypertension, and Stroke Council T he term proteomics was coined 20 years ago to describe the large-scale evaluation of proteins in a tissue or blood sample, an endeavor with broad applicability to cardiovascu- lar research. 1 Proteomic approaches are used to (1) scan com- plex biological mixtures and focus on proteins that distinguish groups; (2) catalogue samples that contain hundreds of pro- teins; (3) derive structural information from protein sequenc- ing; (4) separate and identify proteins and peptides that differ by posttranslational modification; (5) analyze protein interac- tion and protein complexes; (6) perform protein quantitation; Downloaded from http://ahajournals.org by on May 21, 2020